About ACS
ACS is a condition that results in sudden and reduced blood flow to the heart. ACS is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and short-term mortality. On the basis of evidence of heart muscle damage and changes in the ST-tracing of the ECG, ACS is classified into three categories: STEMI, NSTEMI, and UA. ACS is treatable if it is diagnosed quickly. The treatment options for ACS vary, depending on the signs, symptoms, and overall health condition.
Analysts forecast the Global ACS market to grow at a CAGR of 13.24 percent over the period 2014-2019.
Read more details @ http://www.bigmarketresearch.com/global-acute-coronary-syndrome-acs-2015-2019-market
Covered in this Report
The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA. This report covers the present scenario and the growth prospects of the Global ACS market for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ACS.
Global ACS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ACS market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Astra Zeneca
• BMS
• Eli Lilly
• GSK
• Sanofi
Other Prominent Vendors
• AbbVie
• Amgen
• Bayer
• Boehringer Ingelheim
• Daiichi Sankyo
Market Driver
• Increase in Aging Population
• For a full, detailed list, view our report
Market Challenge
• Multiple Patent Expirations
• For a full, detailed list, view our report
Market Trend
• Increase in Awareness
• For a full, detailed list, view our report
Enquire About Report @...